View Older Stories View More Recent Stories

Dec 18, 2017 11:44AM Pfizer Declares First-Quarter 2018 Dividend
Dec 15, 2017 05:39AM Pfizer (PFE) Granted FDA Approval of XELJANZ (tofacitinib) and XELJANZ XR for Treatment of Active Psoriatic Arthritis
Dec 14, 2017 07:26PM Pfizer Announces FDA Approval of XELJANZ® (tofacitinib) and XELJANZ® XR for the Treatment of Active Psoriatic Arthritis
Dec 14, 2017 07:36AM Pfizer (PFE) Begins Phase 3 Program for PF-04965842 for Moderate-to-Severe Atopic Dermatitis
Dec 14, 2017 07:30AM Pfizer Initiates Phase 3 Program for PF-04965842, a JAK1 Inhibitor in Development for Moderate-to-Severe Atopic Dermatitis
Dec 13, 2017 06:02PM Pfizer (PFE) Announces FDA Approval for Remicade Biosimilar
Dec 13, 2017 06:01PM FDA Approves New Pfizer Biosimilar
Dec 13, 2017 05:11PM Pfizer (PFE) Highlights Data on Phase 3 TRUMENBA (Meningococcal Group B Vaccine)
Dec 13, 2017 05:06PM Phase 3 TRUMENBA® (Meningococcal Group B Vaccine) Data Published in New England Journal of Medicine Demonstrate the Vaccine’s Immunogenicity
Dec 12, 2017 06:38PM Preliminary Data from Servier and Pfizer’s UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials
Dec 12, 2017 04:53PM Pfizer (PFE) Reports FDA Extended Action Date For XELJANZ sNDA in Ulcerative Colitis By Three Months
Dec 12, 2017 04:52PM U.S. Food And Drug Administration Extends Action Date For XELJANZ® (Tofacitinib) Supplemental New Drug Application In Ulcerative Colitis By Three Months
Dec 11, 2017 07:10AM Spark Therapeutics (ONCE) and Pfizer (PFE) Announce L-T Prelim. Data Showing Consistent and Sustained Factor IX Levels in Hemophilia B at ASH Meeting
Dec 11, 2017 07:00AM Spark Therapeutics and Pfizer Announce Longer-term Preliminary Data Showing Consistent and Sustained Factor IX Levels in Hemophilia B at 59th American Society of Hematology (ASH) Annual Meeting and Ex
Dec 11, 2017 07:00AM Spark Therapeutics and Pfizer Announce Longer-term Preliminary Data Showing Consistent and Sustained Factor IX Levels in Hemophilia B at 59th American Society of Hematology (ASH) Annual Meeting and Ex
Dec 8, 2017 08:37AM Pfizer (PFE) Announces Talazoparib Significantly Extends PFS in Phase 3 EMBRACA Trial of Patients with Metastatic Breast Cancer
Dec 8, 2017 08:30AM Talazoparib Significantly Extends Progression-Free Survival in Phase 3 EMBRACA Trial of Patients with Metastatic Breast Cancer
Dec 6, 2017 05:01PM Spark Therapeutics (ONCE), Pfizer (PFE) Announce Publication in NEJM of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B
Dec 6, 2017 05:00PM Spark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B
Dec 6, 2017 05:00PM Spark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B
Dec 6, 2017 07:31AM Pfizer (PFE) Says Updated Data from Phase 3 Trial of IBRANCE Plus Letrozole in ER+, HER2- Metastatic Breast Cancer Confirm Improvement in PFS
Dec 6, 2017 07:30AM Updated Data from Phase 3 Trial of IBRANCE® (palbociclib) Plus Letrozole in ER+, HER2- Metastatic Breast Cancer Confirm Improvement in Progression-Free Survival
Dec 5, 2017 08:00AM Bristol-Myers Squibb and Pfizer Alliance Urge People to ‘Tune in to AFib, Take Note of Stroke Risk’
Dec 1, 2017 05:38AM Pfizer (PFE) Reports Agreement with Basilea Pharmaceutica Ltd to Develop and Commercialize CRESEMBA (isavuconazole) in China and Asia Pacific Region
Dec 1, 2017 01:22AM Pfizer Enters into Agreement to Develop and Commercialize CRESEMBA® (isavuconazole) in China and Asia Pacific Region
Nov 28, 2017 08:10AM Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients with Pre-Treated Advanced Gastric Cancer
Nov 28, 2017 08:04AM Merck (MRK) and Pfizer (PFE) Announce Phase III JAVELIN Gastric 300 Study in Patients With Pre-Treated Advanced Gastric Cancer Did Not Meet Primary Endpoint
Nov 28, 2017 08:00AM Merck and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients With Pre-Treated Advanced Gastric Cancer
Nov 16, 2017 04:59PM Pfizer (PFE) Granted FDA Approval for SUTENT (sunitinib malate)
Nov 16, 2017 04:58PM Pfizer Receives FDA Approval for SUTENT® (sunitinib malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma
Nov 10, 2017 04:16PM BMS (BMY)-Pfizer (PFE) Alliance to Unveil Real-World Data Analyses Associated with Oral Anticoagulants in NVAF
Nov 10, 2017 04:13PM BMS-Pfizer Alliance to Unveil Real-World Data Analyses - Cost, Safety and Comparative Effectiveness Findings Associated with Oral Anticoagulants in Non-Valvular Atrial Fibrillation
Nov 7, 2017 07:16AM Spark Therapeutics (ONCE), Pfizer (PFE) Amend Pact for Investigational SPK-9001 in Hemophilia B
Nov 7, 2017 07:15AM Spark Therapeutics and Pfizer Amend License Agreement for Investigational SPK-9001 in Hemophilia B
Nov 1, 2017 04:15PM Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting
Oct 29, 2017 07:01PM One Year Maintenance and Switching Data in Patients with Crohn’s Disease Support the Use of INFLECTRA®* (infliximab CT-P13) in IBD¹
Oct 23, 2017 08:30PM Corning to Showcase Latest in Pharmaceutical Glass Technologies at CPhI Worldwide in Frankfurt, Germany
Oct 16, 2017 07:02AM Pfizer (PFE) Reports Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer
Oct 16, 2017 07:00AM Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer
Oct 12, 2017 08:04AM Pfizer (PFE) Granted FDA Approval for LYRICA CR (Pregabalin)
Oct 12, 2017 08:00AM U.S. FDA Approves LYRICA® CR (pregabalin) Extended-Release Tablets CV
Oct 10, 2017 06:46AM Pfizer (PFE) Says it's Reviewing Strategic Alternatives for Consumer Healthcare Business
Oct 10, 2017 06:45AM Pfizer Reviewing Strategic Alternatives for Consumer Healthcare Business
Oct 5, 2017 08:00AM Pfizer Launches Novel Programs to Put Important Support Services at the Fingertips of Cancer Patients
Sep 27, 2017 08:30AM Pfizer Declares 32-Cent Fourth-Quarter 2017 Dividend
Sep 27, 2017 06:40AM Merck KGaA, Pfizer (PFE) Announce Bavencio Approval for Merkel Cell Carcinoma in Japan
Sep 27, 2017 04:00AM Bavencio (avelumab) Approved for Merkel Cell Carcinoma in Japan
Sep 26, 2017 09:21AM Patti LaBelle and Pfizer Work Together to Educate Baby Boomers About the Risk of Pneumococcal Pneumonia
Sep 25, 2017 07:00AM SpringWorks Therapeutics Launches with $103M in Series A Funding and Rights to Four Clinical Programs
Sep 21, 2017 01:41PM National Sickle Cell Disease Poll of African Americans Dispels Long-Held Views
View More Recent Stories View Older Stories